Interim long-term data from the ongoing ralinepag phase 3
ADVANCE EXTENSION open-label study to be presented at a mini
symposium
An annual update of the preliminary baseline data from the TETON
phase 3 studies of inhaled treprostinil in idiopathic pulmonary
fibrosis will be presented at a poster session
United Therapeutics Corporation (Nasdaq: UTHR), a public
benefit corporation, today announced that recent research across
its commercial and development portfolio will be presented at the
American Thoracic Society (ATS) International Conference in
San Francisco on May 16-21, 2025.
At ATS, United Therapeutics is sponsoring several events
including the Respiratory Innovation Summit and the ATS Research
Program Benefit Networking Event, and the company is hosting the
Jenesis Innovative Research Awards™ Ceremony.
“Our series of posters and presentations at ATS will showcase
the most recent findings on several products across our core
portfolio and ongoing development pipeline,” said Andrew Nelsen,
PharmD, Vice President, Global Medical Affairs at United
Therapeutics. “We are pleased to present additional interim
efficacy data from the ADVANCE EXTENSION open-label study
evaluating ralinepag for pulmonary arterial hypertension, which has
the potential, through once-daily dosing, to fundamentally change
the positioning of prostacyclins in the treatment paradigm.”
Posters, mini-symposia, and discussion sessions
include:
Thematic poster session. Sunday, May 18, 11:30 a.m. to 1:15 p.m.
PT: A48/P1624 – TETON Phase 3 Clinical Trials of Inhaled
Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis:
Annual Update of Preliminary Baseline Data. Presented by Steven
D. Nathan, M.D., Inova Fairfax Hospital.
Thematic poster session. Sunday, May 18, 11:30 a.m. to 1:15 p.m.
PT: A48/P1623 – TETON-PPF Clinical Trial of Inhaled Treprostinil
for the Treatment of Progressive Pulmonary Fibrosis: Preliminary
Baseline Demographics. Presented by Steven D. Nathan, M.D.,
Inova Fairfax Hospital.
Poster discussion session. Sunday, May 18, 2:15 p.m. to 4:15
p.m. PT: A104/908 – Expert Nurse Insights on the Future of
Parenteral Prostacyclin Pumps for Pulmonary Arterial
Hypertension. Presented by Lori Reed, N.P., Piedmont
Healthcare.
Rapid abstract poster discussion session. Monday, May 19, 9:15
a.m. to 11:15 a.m. PT: B26/410 – The Minimal Important
Difference in NT-proBNP in Various Forms of Pulmonary
Hypertension. Presented by Stephen Mathai, M.D., MHS, Johns
Hopkins School of Medicine.
Mini Symposium. Monday, May 19, 3:15 p.m. to 3:27 p.m. PT: B96 –
Ralinepag Treatment to Achieve and Maintain REVEAL Lite 2 Low
Risk Status: Interim Results of ADVANCE EXTENSION. Presented by
Ray Benza, M.D., Icahn School of Medicine at Mount Sinai
Center.
Thematic poster session. Tuesday, May 20, 11:30 a.m. to 1:15
p.m. PT: C58/P1412 – Hemodynamic Phenotypes of Interstitial Lung
Disease Patients Enrolled in the PHINDER Study. Presented by
Debabrata Bandyopadhyay, MBBS, M.D., FCCP, FRCP, FACP, University
of South Florida.
Thematic poster session. Tuesday, May 20, 11:30 a.m. to 1:15
p.m. PT: C58/P1403 – Screening of Pulmonary Hypertension in
Interstitial Lung Disease in the PHINDER Study: A Comparison of
Physician Gestalt with Hemodynamics. Presented by Sandeep
Sahay, M.D., Houston Methodist Hospital.
Thematic poster session. Tuesday, May 20, 11:30 to 1:15 p.m. PT:
C57/P1390 – Efficacy and Safety of Oral Treprostinil in
Intermediate-High Risk Pulmonary Arterial Hypertension: A
FREEDOM-EV Subgroup Analysis. Presented by Jim White, M.D.,
Ph.D., University of Rochester.
Thematic poster session. Tuesday, May 20, 11:30 a.m. to 1:15
p.m. PT: C57/P1393 – Thrombocytopenia Associated with
Epoprostenol and Treprostinil Alone and in Combination with
Sotatercept. Presented by Mardi Gomberg-Maitland, M.D., M.Sc.,
George Washington University.
Hosted/Sponsored events include:
The 2025 Respiratory Innovation Summit, Friday, May 16 and
Saturday, May 17. Andrew Nelsen, PharmD, United Therapeutics, will
deliver a presentation at 1:00 p.m. PT on Saturday.
The ATS Research Program Benefit, Saturday, May 17, 6:00 p.m. to
7:30 p.m. PT. The benefit will be held at the San Francisco Marriot
Marquis.
The Jenesis Innovative Research Awards Ceremony, Sunday, May 18,
6:30 p.m. to 9:30 p.m. PT. The ceremony will be held at the
InterContinental Mark Hopkins San Francisco.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use
our enthusiasm, creativity, and persistence to innovate for the
unmet medical needs of our patients and to benefit our other
stakeholders. We are bold and unconventional. We have fun, we do
good. We are the first publicly-traded biotech or pharmaceutical
company to take the form of a public benefit corporation
(PBC). Our public benefit purpose is to provide a brighter
future for patients through (a) the development of novel
pharmaceutical therapies; and (b) technologies that expand the
availability of transplantable organs.
You can learn more about what it means to be a PBC here:
unither.com/pbc.
Forward-Looking Statements
Statements included in this press release that are not
historical in nature are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, our efforts to
innovate for the unmet medical needs of our patients, to benefit
our other stakeholders, and to pursue our public benefit purpose of
developing novel pharmaceutical therapies and technologies that
expand the availability of transplantable organs. These
forward-looking statements are subject to certain risks and
uncertainties, such as those described in our periodic reports
filed with the Securities and Exchange Commission, that could cause
actual results to differ materially from anticipated results.
Consequently, such forward-looking statements are qualified by the
cautionary statements, cautionary language, and risk factors set
forth in our periodic reports and documents filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. We claim the protection of the safe
harbor contained in the Private Securities Litigation Reform Act of
1995 for forward-looking statements. We are providing this
information as of April 21, 2025, and assume no obligation to
update or revise the information contained in this press release
whether as a result of new information, future events or any other
reason.
JENESIS INNOVATIVE RESEARCH AWARDS is a trademark of United
Therapeutics Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250421355717/en/
Dewey Steadman at (202) 919-4097 (media/investors) Harry Silvers
at (301) 578-1401 (investors)
https://ir.unither.com/contact-uthr/
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jun 2025 até Jul 2025
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jul 2024 até Jul 2025
